O-1602

O-1602
識別資訊
	IUPAC命名法 5-methyl-4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol; ;
CAS號	317321-41-8
PubChem CID	45073499;
IUPHAR/BPS	5525;
ChemSpider	23014383;
UNII	59F4R2N5N5;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID001018640 ;
化學資訊
化學式	C17H22O2
摩爾質量	258.36 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC1=C[C@@H](C2=C(C)C=C(O)C=C2O)[C@H](C(C)=C)CC1;
	InChI InChI=1S/C17H22O2/c1-10(2)14-6-5-11(3)7-15(14)17-12(4)8-13(18)9-16(17)19/h7-9,14-15,18-19H,1,5-6H2,2-4H3/t14-,15+/m0/s1; Key:KDZOUSULXZNDJH-LSDHHAIUSA-N;

O-1602是一種含氮有機化合物，化學式C
17H
22O
2，屬於一種大麻素，由美國Organix Inc公司開發，化學結構上與異常大麻二酚（Abn-CBD）相似，而和經典的大麻素受體CB₁和CB₂無明顯的成鍵傾向^[1]^[2]^[3]。

參考文獻

^ Ashton JC. The atypical cannabinoid O-1602: targets, actions, and the central nervous system. Central Nervous System Agents in Medicinal Chemistry. September 2012, 12 (3): 233–9. PMID 22831390. doi:10.2174/187152412802430156.
^ Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neuroscience Letters. August 2011, 500 (1): 72–6. PMID 21683763. S2CID 3410391. doi:10.1016/j.neulet.2011.06.004.
^ Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflammatory Bowel Diseases. August 2011, 17 (8): 1651–64. PMC 3116968 . PMID 21744421. doi:10.1002/ibd.21538.